$BBLG

Bone Biologics Corp (BBLG) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders. At the Annual Meeting of stockholders (the “Annual Meeting”) of Bone Biologics Corporation (the “Company”), held on September 28, 2026, the Company’s stockholders voted on the matters described below. The number of sh

Bone Biologics (BBLG, BBLGW) added six Australian hospital sites to its NB1 spinal fusion clinical trial, doubling participation and accelerating enrollment. The company expects to complete enrollment by year-end 2026 and aims to gather 12-month follow-up data. CEO Jeff Frelick highlighted the expansion's role in increasing patient access and reducing center reliance. The trial evaluates NB1's safety and effectiveness in 30 adults with degenerative disc disease. Bone Biologics has a cash runway

Bone Biologics (BBLG) said it extended the validated shelf life of its rhNELL-1 protein to 32 months, citing improved manufacturing, storage, and distribution flexibility for its lead candidate NB1. CEO Jeff Frelick linked the milestone to readiness for ongoing NB1 first-in-human work. The stock was last at $0.65, down 28% and at a 52-week low.

Bone Biologics (Nasdaq: BBLG, BBLGW) issued a shareholder update on NB1 progress in 1H 2026. The company completed a private placement in July 2026 raising about $3.0 million gross, with warrants that could add up to about $6.0 million if exercised. It said rhNELL-1 shelf life was extended to 29 months and it expects NB1 first-in-human enrollment completion by year-end.

Bone Biologics Corp (BBLG) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 6 ex10-1.htm EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “ Agreement ”) is dated as of July 7, 2026, between Bone Biologics Corporation, a Delaware corporation (the “ Company ”), and each purchaser identified on the signatur

Bone Biologics (BBLG) said it will sell 2.11M shares or pre-funded warrants plus Series F and short-term Series G warrants to a single institutional investor at $1.42 per share. Gross proceeds are expected at about $3M, with up to about $6M more if warrants are exercised. Net proceeds will fund trials, patents, and working capital. Closing expected July 9, 2026.

Bone Biologics (Nasdaq: BBLG) announced a private placement priced at-the-market under Nasdaq rules with a single healthcare institutional investor. It will issue 2,112,677 shares (or pre-funded warrants) plus Series F and short-term Series G warrants at $1.42/share. Gross proceeds are ~$3.0M upfront, up to ~$6.0M if warrants are fully exercised. Net proceeds fund clinical trials, patents, and working capital; closing expected July 9, 2026.

Bone Biologics Corp (BBLG) stocks have seen a 10.33% increase due to advancements in spinal therapies, despite recent financial reports indicating declines in net income and total assets. The company is at a crucial juncture, balancing promising product development with financial challenges. While market volatility exists, the company's strong balance sheet and focus on strategic adjustments offer potential for future gains, urging investors to weigh product innovation against cost pressures.

Bone Biologics' trading volume surged to 17.22M, far above its 38.8K average. The company expects $5 million from the offering, with up to $10 million more if warrants are exercised. Market-moving news hits Benzinga Pro first-get a 30-minute edge and save 60% this 4th of July.